Laquinimod Prospects Seen Small After RRMS CONCERTO Trial Failure
Teva has no current plans to further pursue laquinimod in relapsing-remitting multiple sclerosis after the investigational asset, developed by Sweden's Active Biotech, failed in the CONCERTO Phase III trial.
You may also be interested in...
Impending clinical trial readouts will indicate whether pharmaceutical companies are on the right track to develop new investigational agents against the cause of the neurodegenerative disorder, Huntington's disease.
Roche's strong first quarter and promising array of innovative medicines left investors wondering why it didn't also lift its financial guidance for the year.
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.